JnJ gets positive CHMP opinion for Rybrevant, chemotherapy combo for first-line treatment of patients with advanced non-...
Belgium: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of RYBREVANT (amivantamab) in …